HOME >> MEDICINE >> NEWS
Pain relief could be easy with a simple injection

A recent study, published in the journal Pain Practice, identified situations in which injections of local anesthetic would be the best treatment for pain and reduce unnecessary risk and procedural costs.

While the use of sympathetic blocks (injections) is controversial, in this study, 20 patients suffering from complex regional pain syndrome (CRPS) were given injections to examine the method's contribution "as prospective predictors of outcome."

The patients, who exhibited allodynia, or pain with light touch, were given an initial "diagnostic" injection after which results were analyzed to determine if further treatments would be advantageous. This treatment consists of injections into the sympathetic nerves that run along the front side of the spinal column.

Those who showed at least a 50% improvement were treated with subsequent blocks. Patients who did show initial improvement were considered to have "sympathetically maintained pain" (SMP) and were also more likely to experience greater long-term improvement as well. Cases in which patients did not have significant improvement were considered to have "sympathetically independent pain" (SIP) and no further treatment was given.

Previous studies by Cepeda et al (1) showed that less than one-third of CRPS patients are likely to respond to this type of procedure.

"Reserving these invasive procedures for patients who will receive the greatest benefit could have significant value by reducing unnecessary risk for adverse events, as well as significant economic benefit by limiting the costs associated with unnecessary procedures," states lead researcher, Dr. Craig T. Hartrick.

Although this study was not randomized and was not placebo-controlled, it "speaks to the rational use of sympathetic block" and suggests that this procedure is especially useful when allodynia is present.


'"/>

Contact: Sharon Agsalda
medicalnews@bos.blackwellpublishing.net
781-388-8507
Blackwell Publishing Ltd.
18-Nov-2004


Page: 1

Related medicine news :

1. Doctor suggested cannabis for pain relief, says one in six medicinal users in the UKMUHC study
2. AGI and USGS provide unique tsunami disaster relief
3. Workers with carpal tunnel find relief with night-time splinting
4. Two days of post-surgical pain relief now possible with just one shot
5. DepoDur found to be innovative option for postoperative pain relief
6. Significant pain relief following gastric bypass surgery
7. Circumcised newborns respond best to anesthetic relief
8. Severe pain relief may be possible with a common anesthetic drug
9. Getting relief from pain can be shocking
10. Adding menthol to topical creams for osteoarthritis provides significant pain relief
11. Off-label use of migraine drug gives children relief, study says

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pain relief could easy with simple injection

(Date:3/2/2015)... March 02, 2015 Over the last ... among leading vendors seeking to expand their geographic presence ... is expected to reach $6.2 billion by 2019 at ... America including the U.S. and Canada and a major ... However developing regions such as Asia-Pacific including China and ...
(Date:3/2/2015)... The minimally invasive surgical instruments ... of 6.1% to reach $14,133.0 million by 2019 ... such as advantages of minimally invasive surgeries over ... minimally invasive surgeries and increasing number of surgical ... global minimally invasive surgical instruments market. , For ...
(Date:3/2/2015)... 02, 2015 LegitScript, LLC, ... certification programs, including those for Internet pharmacy ... safety and classification, has launched a certification ... The new program, called iCareRx , ... regarding the identity of the owner/operator of ...
(Date:3/2/2015)... Atlantic Information Services, Inc. (AIS) is pleased to ... Plans: 2015 , the all-new 12th edition of the ... market, with enrollment data and contact information for health ... as a printed book containing the full directory and ... and charts, as well as an electronic version, AIS’s ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Regulatory ... focused on quality, regulatory and technical consulting, announces ... Chief Operating Officer. , Before joining RCA, ... leading R&D teams in all aspects of developing ... positions at Covidien (Medtronic), Regulatory Compliance Associates Inc., ...
Breaking Medicine News(10 mins):Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ... the successful completion of a Phase 1 clinical ... DUR-928 is an endogenous, small-molecule, new chemical entity ... diseases such as nonalcoholic fatty liver disease (NAFLD) ... injuries such as acute kidney injury (AKI).        ...
(Date:3/2/2015)... 2, 2015  Intrexon Corporation (NYSE: ... announced its fourth quarter and full year results ... Recent Developments: , Acquired ActoGeniX, a European ... in cellular therapeutics and other innovative products.  Its ... food-grade microbes ( Lactococcus lactis ) to generate ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
Cached News: